Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Shares Outstanding (Diluted Average) (2021 - 2025)

Spero Therapeutics (SPRO) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $56.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 4.48% year-over-year to $56.3 million, compared with a TTM value of $56.3 million through Sep 2025, up 4.48%, and an annual FY2024 reading of $54.0 million, up 1.98% over the prior year.
  • Shares Outstanding (Diluted Average) was $56.3 million for Q3 2025 at Spero Therapeutics, roughly flat from $56.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $56.3 million in Q3 2025 and bottomed at $29.5 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $45.6 million, with a median of $52.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 61.09% in 2023, then grew 1.9% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $30.9 million in 2021, then rose by 21.65% to $37.6 million in 2022, then soared by 40.98% to $53.0 million in 2023, then increased by 1.98% to $54.0 million in 2024, then rose by 4.15% to $56.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for SPRO at $56.3 million in Q3 2025, $56.0 million in Q2 2025, and $55.4 million in Q1 2025.